Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow RAPP by emailGet an email when RAPP pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about RAPP, unsubscribe in one click. Privacy
📣 What RAPP Says Is Next
in 2027 · “IND-enabling activities for RAP-219's long-acting injectable formulation continue, with initial Phase 1 pharmacokinetic data expected in 2027. · RAP-641 α6β4 Program Continues to Progress Toward IND Submission.”
Company press release, Aug 5, 2026 · SEC filing
fourth quarter of 2026 · “The majority of patients from the RAP-219 Phase 2 trial in FOS have now enrolled in the open-label long term safety trial, with initial data expected in the fourth quarter of 2026. · Follow-up Phase 2a Data Continues to Support RAP-219’s Differentiated Profile.”
Company press release, Aug 5, 2026 · SEC filing
4Q 2026 · “China National Medical Products Administration (NMPA) approved the Investigational New Drug (IND) application for RAP-219 Phase 3 trials in FOS; Tenacia expects patient recruitment in China to begin in 4Q 2026.”
Company press release, Aug 5, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full RAPP picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RAPP and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.